A review of thromboembolic complications in pregnancy.

Combined with the enlarging uterus compressing the venous system of the pelvis and the vessel trauma incurred in delivery, an increase in clotting factor production in pregnancy predisposes the gravid patient to the peril of thromboembolism. When a patient has an inherited thrombophilia and becomes pregnant, this combination of risk factors in the presence of pregnancy may be the tipping point, pushing the coagulation cascade into an activated state. All thrombophilias, deep vein thrombosis, and pulmonary embolism are factors associated with complications in pregnancy that may lead to catastrophic consequences.

Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism in at-risk pregnant women: a review.

Certain pregnant populations are at high risk of developing venous thromboembolism (VTE) during pregnancy. Patients at particularly high risk of VTE are those with a history of VTE, thrombophilia or adverse pregnancy outcomes or with mechanical heart valves. In these high-risk patients, evidence-based guidelines recommend the use of thromboprophylaxis.

Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes.

Venous thromboembolism and adverse pregnancy outcomes are potential complications of pregnancy. Numerous studies have evaluated both the risk factors for and the prevention and management of these outcomes in pregnant patients. This consensus group was convened to provide concise recommendations, based on the currently available literature, regarding the use of antithrombotic therapy in pregnant patients at risk for venous thromboembolic events and adverse pregnancy outcomes.

Extramembranous placement of an air-coupled vs. transducer-tipped intrauterine pressure catheter.

Objective: To compare the rate of extramembranous placement between 2 types of intrauterine pressure catheter.

Study Design: Women were randomized to a transducer-tipped intrauterine pressure catheter or an air-coupled intrauterine pressure catheter from October 1998 to August 1999. Women were eligible for the study if their attending physicians decided to place an intrauterine pressure catheter.

Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester.

Background: Methotrexate has multiple therapeutic uses in women of reproductive age including treatment for ectopic pregnancy, neoplastic disease, autoimmune disorders, and inflammatory conditions. More frequent use of methotrexate may result in an increased number of exposures in pregnant women and their fetuses.

Case: A 16-year-old gravida 1, para 0 used oral methotrexate treatment of 7.